Parkinson’s

FDA
#Drug approvals #Parkinson's #Pharmaceuticals

First live biotherapeutic approved to treat Parkinson’s disease 

The US Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for MRx0005 and MRx0029, two 4D Pharma Live Biotherapeutics (LBPs). The company expects to initiate a first-in-human Phase I clinical trial in people with Parkinson’s disease in mid-2022.  Context  Parkinson’s disease… Read More

#News

#Collaboration #Drug therapy #Neuroscience #Parkinson's

Collaboration targeting neuroinflammation to slow Parkinson’s  

Parkinson’s UK and Domainex have collaborated to develop small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s Disease.   Context  Inflammation is vital for defending the body from infections, injuries and toxins. However, in Parkinson’s there is excessive chronic inflammation within the brain. Read More

#News

#Clinical research #Parkinson's

New Parkinson’s study investigates treatment of non-motor symptoms  

The design for two new trials investigating opicapone in the treatment of non-motor symptoms in patients with motor fluctuations in Parkinson’s disease (PD) have been presented at the International Parkinson and Movement Disorder Society’s Virtual Congress (MDS Virtual Congress 2021). Usually associated with motor symptoms, opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved in Europe… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News

#Biotherapeutics #Drug development #Parkinson's

Innovative CNS medicines partnership announced

Bial and Medis have partnered on two of Bial’s proprietary drugs: Zebinix (eslicarbazepine acetate) and Ongentys (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys in Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia,… Read More

#News

#Drug design #Drug development #Drug discovery #Neuroscience #Parkinson's

IRICoR and Valence collaborate in AI drug design for Parkinson’s

IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More

#News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#Clinical specialities #Clinical trials #Drug repositioning #Parkinson's

Cancer anti-sickness drug offers hope for Parkinson’s hallucinations

A double-blind clinical trial, will investigate if a drug used to treat nausea in chemotherapy patients, could alleviate hallucinations in people with Parkinson’s. Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, is partnering with UCL, and investing £1 million in a pioneering Phase II clinical trial to… Read More

#Editor's Choice #News